Admissions caused by adverse drug events to internal medicine and emergency departments in hospitals: a longitudinal population-based study

[1]  S. Schneeweiss,et al.  First results from an intensified monitoring system to estimate drug related hospital admissions. , 2001, British journal of clinical pharmacology.

[2]  M. Hippius,et al.  Adverse drug reaction monitoring--digitoxin overdosage in the elderly. , 2001, International journal of clinical pharmacology and therapeutics.

[3]  F. Haramburu,et al.  Admissions to hospital caused by adverse drug reactions: cross sectional incidence study , 2000, BMJ : British Medical Journal.

[4]  L. Naldi,et al.  Risk of Stevens-Johnson syndrome and toxic epider mal necrolysis during first weeks of antiepileptic therapy: a case-control study , 1999, The Lancet.

[5]  Jason Lazarou,et al.  Incidence of Adverse Drug Reactions in Hospitalized Patients , 1999 .

[6]  R. Stern,et al.  Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions. , 1999, Lancet.

[7]  E. Roughead,et al.  Drug‐related hospital admissions: a review of Australian studies published 1988‐1996 , 1998, The Medical journal of Australia.

[8]  M Maclure,et al.  Case–crossover and case–time–control designs as alternatives in pharmacoepidemiologic research , 1997, Pharmacoepidemiology and drug safety.

[9]  J Hasford,et al.  Adverse drug reaction monitoring—cost and benefit considerations. Part II: cost and preventability of adverse drug reactions leading to hospital admission , 1997, Pharmacoepidemiology and drug safety.

[10]  D. Classen,et al.  Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. , 1997, JAMA.

[11]  J. Avorn.  Putting adverse drug events into perspective. , 1997, JAMA.

[12]  J. Hallas,et al.  Drug related admissions to medical wards: a population based survey. , 1992, British journal of clinical pharmacology.

[13]  R. Royer,et al.  ADVERSE DRUG REACTION MONITORING: DOING IT THE FRENCH WAY , 1985, The Lancet.